Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Orbicular Pharmaceutical Technologies Private Limited maintains 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, yet they are all situated within 1 distinct art unit. This indicates that while the company is interacting with multiple individuals, its current legal challenges are situated within 1 distinct art unit at the patent office. The concentration in the assigned unit implies that the pending applications are being evaluated within the same administrative framework.
The busiest examiner for this portfolio is WHITROCK, ZACHARIAH KIRBY, who is currently managing 1 pending office action. Given that 3 distinct examiners are each handling a portion of the 3 pending actions, the workload is distributed across the assigned staff. This distribution requires the company to address the specific examination styles of 3 different individuals even as they operate within the same art unit. For the practitioner, this requires a strategy that addresses the unique concerns of each assigned examiner involved in the Biotechnology & Pharmaceuticals filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITROCK, ZACHARIAH KIRBY | 1 | 100.0% | +0.0% |
| GARYU, LIANKO G | 1 | 66.0% | +45.4% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724799 | SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE | WHITROCK, ZACHARIAH KIRBY | — |
| 18712828 | STABLE INJECTABLE COMPOSITIONS OF GLP-2 PEPTIDE | GARYU, LIANKO G | — |
| 18569581 | IMPROVED TREATMENT METHODS FOR CABAZITAXEL | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712828 | STABLE INJECTABLE COMPOSITIONS OF GLP-2 PEPTIDE | GARYU, LIANKO G | — |
| 18569581 | IMPROVED TREATMENT METHODS FOR CABAZITAXEL | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724799 | SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE | WHITROCK, ZACHARIAH KIRBY | — | §103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18712828 | STABLE INJECTABLE COMPOSITIONS OF GLP-2 PEPTIDE | GARYU, LIANKO G | — | §102§103§112Other | Non-Final OA | — | Pending | May 23, 2024 |
| 18569581 | IMPROVED TREATMENT METHODS FOR CABAZITAXEL | VALLE, ERNESTO | 1623 | §102§103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial